BioSpace News Archive

Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the voting results of the Company’s Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included t

Teijin Pharma Limited (“Teijin Pharma”), the core company of the Teijin Group ‘s healthcare business headquartered in Tokyo, Japan , and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing , China , jointly announced that they have entered into a strategic col

As the COVID-19 vaccines roll out across the country, the record-setting pace of the vaccine development may seem to many like an overnight success story. In reality, it was built on more than a decade of research into other viruses at the U.S Department of Energy’s (DOE) Argonne National Laboratory’s Advanced Photon Source (APS). This press release features multimedia. View the full release here: https://www.businesswi

VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is concluding a successful year marked by extensive hiring and expanded service offerings. This growth has allowed the company to successfully take on an increasing number of large, global clinical

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of common stock, (ii) 1,000,000 pre-funded common stock Warrants (i.e., warrants to purchase shar

National Dialysis Accreditation Commission, LLC (NDAC) is pleased to announce a new collaboration with Ascellon Corporation to provide Life Safety Code (LSC) surveys for NDAC clients. The new agreement ensures that NDAC’s dialysis provider clients continue to receive the fastest accreditation service and Medicare deemed status

Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of

Plan to study bamlanivimab in a diverse group of participants, including Native American communities

Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced that it will be added to the Russell 2000® and 3000® Indexes effective December 21, 2020, following Russell’s quarterly additions of select initial public offerings.

Keith Berman, the CEO of DECN, was charged yesterday in Los Angeles by the United States Department of Justice with one count of securities fraud and one count of making a false statement to government officials.